Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma
The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontlin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontline therapy (later amended to six months) and double-hit lymphoma were excluded. In this case report, we present the clinical course of an 85-year-old woman with primary refractory, double-hit DLBCL who was successfully treated with tafasitamab plus lenalidomide following disease progression on the R-mini-CHOP regimen.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Prof. Andreas Holbro, University Hospital Basel, Basel, Switzerland
Prof. Christoph Renner, Hospital Hirslanden, Zurich, Switzerland
Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland
Received on January 09, 2025; accepted after peer review on March 20, 2025; published online on March 23, 2025. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |